🇺🇸 FDA
Pipeline program

tulisokibart, tulisokibart, Placebo to MK-7240

MK-7240-001

Phase 3 small_molecule active

Quick answer

tulisokibart, tulisokibart, Placebo to MK-7240 for Ulcerative colitis is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Ulcerative colitis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials